{"id":"W2129967156","doi":"10.1177/1352458513507821","title":"Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial","year":2013,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":351,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital; Ottawa Hospital; University of Ottawa","funders":"IC Design Education Center; National Institutes of Health; Serono Symposia International Foundation; Bayer HealthCare; Acorda Therapeutics; Multiple Sclerosis Society; Biogen; Sanofi; National Multiple Sclerosis Society","keywords":"Teriflunomide; Medicine; Multiple sclerosis; Internal medicine; Discontinuation; Clinical endpoint; Dimethyl fumarate; Physical therapy; Expanded Disability Status Scale; Randomized controlled trial; Immunology; Fingolimod","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00316657,0.001724461,0.004067123,0.0004976938,0.0006090971,0.001229006,0.0009999454,0.002649052,0.008892721],"category_scores_gemma":[0.00295616,0.0007026711,0.002911532,0.0005858339,0.001238374,0.001093276,0.0004505685,0.002978643,0.001273005],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007405159,"about_ca_system_score_gemma":0.001540245,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009435833,"about_ca_topic_score_gemma":0.00193108,"domain_scores_codex":[0.9987414,0.0007841577,0.00009124412,0.0001563842,0.00008839653,0.0001384346],"domain_scores_gemma":[0.9984999,0.0005134398,0.0004258336,0.0001192355,0.00009252613,0.0003490538],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9828189,0.003015766,0.0002311137,0.0009163184,0.0006524828,0.00004959657,0.00005225119,0.0001319997,0.001639393,0.00005679256,0.0004910344,0.009944295],"study_design_scores_gemma":[0.9779669,0.0208944,0.0004465433,0.00003635322,0.0001614975,0.00002114798,0.000008441054,0.0001019158,0.00007613863,0.00006310747,0.0002172395,0.000006303984],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9631786,0.01596545,0.001287079,0.001850275,0.001331253,0.0117434,0.001750058,0.0002871272,0.0026067],"genre_scores_gemma":[0.9571027,0.008580066,0.003471133,0.002958046,0.001159312,0.0209754,0.001387274,0.00005487169,0.004311258],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008892721,"threshold_uncertainty_score":0.0297491,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08007616229311648,"score_gpt":0.2890024800529596,"score_spread":0.2089263177598432,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}